RxSight (RXST)
(Delayed Data from NSDQ)
$47.41 USD
+0.64 (1.37%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $47.39 -0.02 (-0.04%) 4:24 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for RxSight, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 127 | 106 | 159 | 69 | -99,999 |
Receivables | 20 | 11 | 5 | 3 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 17 | 15 | 8 | 8 | NA |
Other Current Assets | 4 | 3 | 4 | 1 | NA |
Total Current Assets | 168 | 135 | 176 | 82 | NA |
Net Property & Equipment | 11 | 10 | 11 | 13 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 1 | 2 | 1 | 1 | NA |
Total Assets | 183 | 150 | 193 | 101 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 4 | 3 | 2 | 1 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 15 | 13 | 8 | 4 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 5 | NA |
Total Current Liabilities | 21 | 17 | 11 | 12 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 40 | 40 | 24 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 57 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 22 | 60 | 54 | 98 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 353 | NA |
Common Stock (Par) | 0 | 0 | 0 | 81 | NA |
Capital Surplus | 755 | 636 | 618 | 0 | NA |
Retained Earnings | -595 | -546 | -479 | -431 | NA |
Other Equity | 0 | 0 | 0 | -1 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 160 | 90 | 138 | 3 | NA |
Total Liabilities & Shareholder's Equity | 183 | 150 | 193 | 101 | NA |
Total Common Equity | 160 | 90 | 138 | -351 | 0 |
Shares Outstanding | 35.80 | 27.70 | 27.30 | NA | NA |
Book Value Per Share | 4.48 | 3.25 | 5.06 | 0.00 | 0.00 |
Fiscal Year End for RxSight, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 125 | 127 | 132 | 147 |
Receivables | NA | 22 | 20 | 15 | 13 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 19 | 17 | 19 | 18 |
Other Current Assets | NA | 3 | 4 | 2 | 2 |
Total Current Assets | NA | 169 | 168 | 168 | 180 |
Net Property & Equipment | NA | 12 | 11 | 10 | 11 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 183 | 183 | 182 | 195 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 5 | 4 | 4 | 4 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 12 | 15 | 13 | 11 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 18 | 21 | 19 | 17 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 20 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 19 | 22 | 20 | 38 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 768 | 755 | 747 | 730 |
Retained Earnings | NA | -604 | -595 | -585 | -573 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 164 | 160 | 161 | 157 |
Total Liabilities & Shareholder's Equity | NA | 183 | 183 | 182 | 195 |
Total Common Equity | 0 | 164 | 160 | 161 | 157 |
Shares Outstanding | 36.90 | 37.10 | 35.80 | 35.60 | 33.90 |
Book Value Per Share | 0.00 | 4.42 | 4.48 | 4.54 | 4.64 |